<DOC>
	<DOCNO>NCT02692040</DOCNO>
	<brief_summary>A randomised , placebo control Phase I study investigate safety , tolerability , pharmacokinetics pharmacodynamics G3215 adult subject .</brief_summary>
	<brief_title>Study Gut Hormone Analogue G3215 Adult Subjects</brief_title>
	<detailed_description>Objectives : Primary Objective - To investigate safety tolerability single dos G3215 overweight otherwise healthy male subject . - To investigate safety tolerability multiple dos G3215 overweight male subject mild stable Type 2 diabetes prediabetes . Secondary Objectives • To assess pharmacokinetic ( PK ) profile single multiple ascend dos G3215 overweight otherwise healthy male subject overweight / obese male subject mild stable Type 2 diabetes prediabetes . Exploratory Objective • To investigate effect multiple dos G3215 food consumption , body weight , enteropancreatic hormone change glucose tolerance overweight male subject mild Type 2 diabetes prediabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Adult male age 18 60 year inclusive body mass index ( BMI ) 25.0 35.0 kg/m2 inclusive ; 2 . Subjects otherwise healthy enough participate , determine prestudy medical history , physical examination 12 lead ECG ; 3 . Subjects whose clinical laboratory test result either within normal range outside range abnormality judge clinically relevant acceptable Investigator ; 4 . Subjects negative hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) I II test screen ; 5 . Subjects negative drug abuse alcohol test screen admission ; 6 . Subjects nonsmoker least 3 month precede screening ; 7 . Subjects agree use medically acceptable method contraception least 3 month study drug administration ; 8 . Subjects able willing give write informed consent . 1 . Subjects conform inclusion criterion ; 2 . Subjects clinically relevant history presence gastrointestinal ( especially associate vomit ) , respiratory , renal , hepatic , haematological , lymphatic , neurological ( especially associate balance disorder vomit e.g . migraine labyrinthitis ) , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder ; 3 . Subjects clinically relevant surgical history ; 4 . Subjects currently take thiazolidinediones , dipeptidyl peptidase IV inhibitor ( 'gliptins ' ) , glucagonlike peptide1 ( GLP1 ) analogue , sodiumglucose cotransporter ( SGLT2 ) inhibitor , insulin ; 5 . Subjects history relevant severe atopy e.g . asthma , angioedema require emergency treatment , severe hayfever require regular treatment , severe eczema require regular treatment ; 6 . Subjects history relevant drug hypersensitivity ; 7 . Subjects history alcohol abuse alcohol dependence accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criterion within last two year ; 8 . Subjects history drug substance abuse accord DSMIV criterion within last 2 year ; 9 . Subjects history clinically significant migraine judge Investigator . Subjects include migraine last 3 year ; 10 . Subjects history pancreatitis pancreatic cancer ; 11 . Subjects consume 21 unit alcohol week ( unit = 1 glass wine ( 125 mL ) = 1 measure spirit = ½ pint beer ) ; 12 . Subjects significant infection know inflammatory process screening ; 13 . Subjects acute gastrointestinal symptom time screen admission ( e.g . nausea , vomit , diarrhoea , heartburn ) ; 14 . Subjects acute infection influenza time screen admission ; 15 . Subjects use prescription drug within 2 week first dose . For Part B , patient allow ; monotherapy sulphonylureas , metformin . In addition patient Part B allow take hypolipidaemic and/or antihypertensive treatment , provide dos alter within 4 week prior enter study . Other medication may allow Investigator Sponsor agree affect outcome study safety subject . 16 . Subjects use counter medication exclude routine vitamin paracetamol include megadose ( intake 20 600 time recommended daily dose ) vitamin therapy within 7 day first dose , unless agree clinically relevant Principal Investigator Sponsor ; 17 . Subjects donate blood within 3 month prior screen ; Subjects donate plasma within 7 day prior screen ; Subjects donate platelet within 6 week prior screen 18 . Subjects use investigational drug clinical trial within 3 month first admission date ; 19 . Subjects receive last dose investigational drug great 3 month ago extend followup ; 20 . Subjects previously receive G3215 ; 21 . Subjects vegans dietary restriction ; 22 . Subjects communicate reliably Investigator ; 23 . Subjects unlikely cooperate requirement study ; 24 . History evidence abnormal eat behaviour , observe Dutch Eating Behaviour ( DEBQ ) SCOFF ( Sick , Control , One Stone , Fat , Food ) questionnaires screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>glucagon-like peptide-1</keyword>
</DOC>